Time above threshold plasma concentrations as pharmacokinetic parameter in the comparison of oral and intravenous docetaxel treatment of breast cancer tumors

Author:

van Eijk Maarten1,Beijnen Jos H.12,Huitema Alwin D.R.134

Affiliation:

1. Department of Pharmacy and Pharmacology, Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam

2. Department of Pharmaceutical Sciences, Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University

3. Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht University

4. Department of Pharmacology, Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands

Abstract

Background Prolonging the time which plasma concentrations of antimitotic drugs, such as the taxanes, exceed cytotoxic threshold levels may be beneficial for their efficacy. Orally administered docetaxel offers an undemanding approach to optimize such time above threshold plasma concentrations (tC>threshold). Methods A nonsystematic literature screen was performed to identify studies reporting in-vitro half-maximal inhibitory concentration (IC50) values for docetaxel. Pharmacokinetics of intravenously (i.v.) docetaxel (75 mg/m2) and orally administered docetaxel (ModraDoc006) co-administered with ritonavir (r) given twice daily (30 + 20 mg concomitant with 100 mg ritonavir bis in die) were simulated using previously developed population models. TC>threshold was calculated for a range of relevant thresholds in terms of in-vitro cytotoxicity and plasma concentrations achieved after i.v. and oral administration of docetaxel. A published tumor growth inhibition model for i.v. docetaxel was adapted to predict the effect of attainment of time above threshold levels on tumor dynamics. Results Identified studies reported a wide range of in vitro IC50 values [median 0.04 µmol/L, interquartile range (IQR): 0.0046–0.62]. At cytotoxic thresholds <0.078 µmol/L oral docetaxel shows up to ~7.5-fold longer tC>threshold within each 3-week cycle for a median patient compared to i.v.. Simulations of tumor dynamics showed the increased relative potential of oral docetaxel for inhibition of tumor growth at thresholds of 0.075, 0.05 and 0.005 µmol/L. Conclusion ModraDoc006/r is superior to i.v. docetaxel 75 mg/m2 in terms of median time above cytotoxic threshold levels <0.078 µmol/L. This may indicate superior cytotoxicity and inhibition of tumor growth compared to i.v. administration for relatively docetaxel-sensitive tumors.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cancer Research,Pharmacology (medical),Pharmacology,Oncology

Reference63 articles.

1. Microtubules as a target for anticancer drugs.;Jordan;Nat Rev Cancer,2004

2. Mechanism of action of antitumor drugs that interact with microtubules and tubulin.;Jordan;Curr Med Chem-Anti-Cancer Agents,2002

3. Control of microtubule organization and dynamics: two ends in the limelight.;Akhmanova;Nat Rev Mol Cell Biol,2015

4. Mechanisms of Taxol resistance related to microtubules.;Orr;Oncogene,2003

5. Cytotoxic thresholds of vincristine in a murine and a human leukemia cell line in vitro.;Jackson;Cancer Res,1979

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3